Abstract
Osteoprotegerin (OPG) is a member of the tumour necrosis factor receptor superfamily of cytokines which, in spite of being initially described as a strong anti-resorptive factor, has lately been considered as a possible link between bone and vascular disease. In the last few years, several studies have evidenced its close relationship with the development of diabetes. In this review, we analyse the role of OPG in diabetic patients and its links with the most relevant associated diseases such as atherosclerosis, hypertension, endothelial dysfunction and diabetic nephropathy, as well as its connection with related pathologies as fibrosis, obesity and metabolic syndrome.
Keywords: Osteoprotegerin, diabetes, metabolic syndrome, fibrosis, blood pressure, endothelial dysfunction, atherosclerosis, nephropathy, cardiovascular disease, angiopathy, anti-resorptive factor, bone remodelling, RANKL, Src pathways, bone resorption
Current Molecular Medicine
Title: Osteoprotegerin and Diabetes-Associated Pathologies
Volume: 11 Issue: 5
Author(s): A. M. Blazquez-Medela, J. M. Lopez-Novoa and C. Martinez-Salgado
Affiliation:
Keywords: Osteoprotegerin, diabetes, metabolic syndrome, fibrosis, blood pressure, endothelial dysfunction, atherosclerosis, nephropathy, cardiovascular disease, angiopathy, anti-resorptive factor, bone remodelling, RANKL, Src pathways, bone resorption
Abstract: Osteoprotegerin (OPG) is a member of the tumour necrosis factor receptor superfamily of cytokines which, in spite of being initially described as a strong anti-resorptive factor, has lately been considered as a possible link between bone and vascular disease. In the last few years, several studies have evidenced its close relationship with the development of diabetes. In this review, we analyse the role of OPG in diabetic patients and its links with the most relevant associated diseases such as atherosclerosis, hypertension, endothelial dysfunction and diabetic nephropathy, as well as its connection with related pathologies as fibrosis, obesity and metabolic syndrome.
Export Options
About this article
Cite this article as:
M. Blazquez-Medela A., M. Lopez-Novoa J. and Martinez-Salgado C., Osteoprotegerin and Diabetes-Associated Pathologies, Current Molecular Medicine 2011; 11 (5) . https://dx.doi.org/10.2174/156652411795976565
DOI https://dx.doi.org/10.2174/156652411795976565 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance
Current Pharmaceutical Design Urinary Exosomal Lipidomics Reveals Markers for Diabetic Nephropathy
Current Metabolomics Inflamm-ageing and senescence in gout: the tale of an old king’s disease.
Current Aging Science Goto-kakizaki Rats: Its Suitability as Non-obese Diabetic Animal Model for Spontaneous Type 2 Diabetes Mellitus
Current Diabetes Reviews Hormones and the Autonomic Nervous System are Involved in Suprachiasmatic Nucleus Modulation of Glucose Homeostasis
Current Diabetes Reviews Periodontal Bacteria Aggravate Chronic Renal Failure Induced by Subtotal Nephrectomy in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Angiotensin (1-7) and other Angiotensin Peptides
Current Pharmaceutical Design Non-dipping Status in Arterial Hypertension: An Overview
Current Vascular Pharmacology Novel Diagnostics R&D for Public Health and Personalized Medicine in Taiwan: Current State, Challenges and Opportunities
Current Pharmacogenomics and Personalized Medicine Abietane Diterpenes as Potential Candidates for the Management of Type 2 Diabetes
Current Pharmaceutical Design Diabetic Retinopathy, Superoxide Damage and Antioxidants
Current Pharmaceutical Biotechnology Angiotensin Peptides as AT2 Receptor Agonists
Current Protein & Peptide Science Gastric Bypass and Diabetes: Past, Present and Future
Current Diabetes Reviews Mitochondrial Dysfunction and Oxidative Stress in Insulin Resistance
Current Pharmaceutical Design Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases
Current Clinical Pharmacology Arterial Stiffness and Type 1 Diabetes: The Current State of Knowledge
Current Diabetes Reviews Intravitreal Inserts of Steroids to Treat Diabetic Macular Edema
Current Diabetes Reviews Natural Medicine:The Genus Angelica
Current Medicinal Chemistry Recent Clinical Trials of Pharmacologic Cardiovascular Interventions in Patients with Chronic Kidney Disease
Reviews on Recent Clinical Trials Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism